邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

真实世界研究：弥合临床实践指南与临床决策之间的距离

施秀青,  阎思宇,  黄桥,  李绪辉,  王永博,  马文昊,  商洪才,  靳英辉

downloadPDF
文章导航 > 协和医学杂志  > 2022 > 优先出版
施秀青, 阎思宇, 黄桥, 李绪辉, 王永博, 马文昊, 商洪才, 靳英辉. 真实世界研究：弥合临床实践指南与临床决策之间的距离[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0217
引用本文: 施秀青, 阎思宇, 黄桥, 李绪辉, 王永博, 马文昊, 商洪才, 靳英辉. 真实世界研究：弥合临床实践指南与临床决策之间的距离[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0217
shu
SHI Xiuqing, YAN Siyu, HUANG Qiao, LI Xuhui, WANG Yongbo, MA Wenhao, SHANG Hongcai, JIN Yinghui. Real World Research: Helping Clinical Practice Guidelines Span the Distance Between Itself and Clinical Decision Making[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0217
Citation: SHI Xiuqing, YAN Siyu, HUANG Qiao, LI Xuhui, WANG Yongbo, MA Wenhao, SHANG Hongcai, JIN Yinghui. Real World Research: Helping Clinical Practice Guidelines Span the Distance Between Itself and Clinical Decision Making[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0217
shu

真实世界研究：弥合临床实践指南与临床决策之间的距离

doi: 10.12290/xhyxzz.2022-0217

  • 1. 烟台毓璜顶医院, 山东烟台 264000;

  • 2. 武汉大学中南医院循证与转化医学中心 武汉大学循证与转化医学中心, 武汉 430071;

  • 3. 武汉大学, 武汉 430071;

  • 4. 北京中医药大学东直门医院 中医内科学教育部和北京市重点实验室, 北京 100700

基金项目: 

国家自然科学基金(82174230)

详细信息
    通讯作者:

    商洪才,E-mail:shanghongcai@126.com

    靳英辉,E-mail:jinyinghuiebm@163.com

  • 中图分类号: R012

Real World Research: Helping Clinical Practice Guidelines Span the Distance Between Itself and Clinical Decision Making

  • 1. Yuhuangding Hospital of Yantai, Yantai, Shandong 264000, China;

  • 2. Center for Evidence-based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China;

  • 3. Wuhan University, Wuhan 430071, China;

  • 4. Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine, Ministry of education and Beijing Key Laboratory of internal medicine of traditional Chinese Medicine, Beijing 100700, China

Funds: 

National Natural Science Foundation of China (82174230)

    摘要
  • 摘要: 临床实践指南是制订临床决策的重要依据，但仍有诸多因素导致医生无法遵循指南，其中一个重要因素为指南的外部有效性受限，最终使得指南无法为临床决策的制订提供足够依据，此为指南与临床决策之间的距离。真实世界研究可增强指南的外部有效性，为临床决策的制订提供依据，为指南提供本土化证据、成本效益及其他方面相关证据，同时可监测指南的实施，弥补传统指南的证据不足，有助于弥合指南与临床决策之间的距离。在指南制订过程中，可考虑纳入高质量的真实世界研究和真实世界证据，以促进指南优化，助力指南质量提升。
    Abstract: Clinical practice guidelines are an important basis for clinical decision-making， but there are still many factors that prevent physicians from following the guidelines， one of which is the limited external validity of the guidelines， which ultimately makes the guidelines unable to provide an adequate basis for clinical decision-making. This forms the distance between the guidelines and clinical decisions. Real-world research can enhance the external validity of the guidelines， provide a basis for clinical decision-making， offer localized evidence for the guidelines， demonstrate evidence of cost-effectiveness and other evidence for the guidelines. It can also monitor the implementation of the guidelines， help to make up for the lack of evidence in the formulation of traditional guidelines， thus help to span the distance between the guidelines and clinical decisions. High-quality real-world studies and real-world evidence may be considered for inclusion in the guideline development process to facilitate guideline optimization and serve as an aid to guideline quality improvement.
    • HTML全文
    • 参考文献(65)
  • [1] Institute of Medicine. Clinical Practice Guidelines We Can Trust.[M]. Washington (DC):National Academies Press (US), 2011.
    [2] U.S. Food and Drug Administration. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices-Guidance for Industry and Food and Drug Administration Staff[EB/OL].(注明发布日期)[注明引用日期].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-wor ld-evidence-support-regulatory-decision-making-medical-devices.
    [3] U.S. Food and Drug Administration. Framework for FDA's Real-World Evidence Program[EB/OL]. https://www.fda.gov/media/124748/download.
    [4] 国家药品监督管理局.真实世界数据用于医疗器械临床评价技术指导原则(征求意见稿)[EB/OL].(注明发布日期)[注明引用日期].https://www.cmde.org.cn/CL0066/20139.html.
    [5] 国家药品监督管理局. http://www.nmpa.gov.cn/WS04/CL2138/373175.html.
    [6] SHERMAN R E, ANDERSON S A, DAL PAN G J, et al. Real-World Evidence-What Is It and What Can It Tell Us?[J]. The New England journal of medicine, 2016, 375:2293-2297.
    [7] NEW J P, BAKERLY N D, LEATHER D, et al. Obtaining real-world evidence:the Salford Lung Study[J]. Thorax, 2014, 69:1152-1154.
    [8] CONCATO J, CORRIGAN-CURAY J. Real-World Evidence-Where Are We Now?[J]. The New England journal of medicine, 2022, 386:1680-1682.
    [9] U.S. Food and Drug Administration. 21st Century Cure Act[EB/OL].(注明发布日期)[注明引用日期]. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-curesact.
    [10] U.S. Food and Drug Administration. Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics Guidance for Industry[EB/OL].https://www.fda.gov/media/124748/download.
    [11] 国家药品监督管理局.国家药监局药审中心关于发布《真实世界研究支持儿童药物研发与审评的技术指导原则(试行)》的通告(2020年第22号)[EB/OL].(注明发布日期)[注明引用日期].https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200901104448101.html.
    [12] ALONSO-COELLO P, IRFAN A, SOL I, et al. The quality of clinical practice guidelines over the last two decades:a systematic review of guideline appraisal studies[J]. Quality&safety in health care, 2010, 19:e58.
    [13] BABJUK M, BURGER M, CAPOUN O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)[J]. European urology, 2022, 81:75-94.
    [14] CHANG S S, BOORJIAN S A, CHOU R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer:AUA/SUO Guideline[J]. The Journal of urology, 2016, 196:1021-1029.
    [15] MORI K,MIURA N,BABJUK M,et al. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma:A systematic review[J]. Urologic oncology, 2020, 38:774-782.
    [16] CHAMIE K, SAIGAL C S, LAI J, et al. Compliance with guidelines for patients with bladder cancer:variation in the delivery of care[J]. Cancer, 2011, 117:5392-5401.
    [17] POSEN A, BENKEN S, KALUZNA S D, et al. Poor guideline adherence in a real-world evaluation of hypertensive emergency management[J]. The American journal of emergency medicine, 2022, 51:46-52.
    [18] CABANA M D, RAND C S, POWE N R, et al. Why don't physicians follow clinical practice guidelines?A framework for improvement[J]. Jama, 1999, 282:1458-1465.
    [19] JIN Y H, TAN L M, KHAN K S, et al. Determinants of successful guideline implementation:a national cross-sectional survey[J]. BMC medical informatics and decision making, 2021, 21:19.
    [20] WONG G W, MIRAVITLLES M, CHISHOLM A, et al. Respiratory guidelines——which real world?[J]. Annals of the American Thoracic Society, 2014, 11 Suppl 2:S85-91.
    [21] GUYATT G H, OXMAN A D, VIST G E, et al. GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ (Clinical research ed), 2008, 336:924-926.
    [22] HERLAND K, AKSELSEN J P, SKJ NSBERG O H, et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?[J]. Respiratory medicine, 2005, 99:11-19.
    [23] HOFFMAN S N, TENBROOK J A, WOLF M P, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty:one-to eight-year outcomes[J]. Journal of the American College of Cardiology, 2003, 41:1293-1304.
    [24] W. BRETT M T H, U. GULLER, H.-R. ZERKOWSKI. CABG vs. PCI in coronary artery disease:what is the evidence?[J]. Card Surg Today, 2006, 2:43-55.
    [25] GRAPOW M T, VON WATTENWYL R, GULLER U, et al. Randomized controlled trials do not reflect reality:real-world analyses are critical for treatment guidelines![J]. The Journal of thoracic and cardiovascular surgery, 2006, 132:5-7.
    [26] KENNEDY-MARTIN T, CURTIS S, FARIES D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results[J]. Trials, 2015, 16:495.
    [27] CHEW S Y, KOH M S, LOO C M, et al. Making Clinical Practice Guidelines Pragmatic:How Big Data and Real World Evidence Can Close the Gap[J]. Annals of the Academy of Medicine, Singapore, 2018, 47:523-527.
    [28] HAYWARD R S. Clinical practice guidelines on trial[J]. CMAJ:Canadian Medical Association journal=journal de l'Association medicale canadienne, 1997, 156:1725-1727.
    [29] 周奇,董冲亚,王业明,等.循证医学理念在指导临床研究与实践中的作用:基于对抗病毒药物治疗新型冠状病毒肺炎的思考[J].中国循证医学杂志, 2022, 22:373-379.
    [30] SCHNEEWEISS S, PATORNO E. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments[J]. Endocrine reviews, 2021, 42:658-690.
    [31] U.S. Food and Drug Administration. FDA expands approved use of metastatic breast cancer treatment to include male patients[EB/OL].(注明发布日期)[注明引用日期].https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635276.htm?utm_campaign=040419_PR_FDA% 20expands% 20use% 20of% 20breast% 20cancer% 20treatment% 20to% 20include% 20male% 20patients&utm_medium=email&utm_source=Eloqua (2019).
    [32] KHAN O, WILLIAMS M J, AMEZCUA L, et al. Multiple sclerosis in US minority populations:Clinical practice insights[J]. Neurology Clinical practice, 2015, 5:132-142.
    [33] WILLIAMS M J, AMEZCUA L, OKAI A, et al. Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis:3-Year Results from ESTEEM[J]. Neurology and therapy, 2020, 9:483-493.
    [34] KLEEBERG U R, LINDE H, G NTHER G, et al. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia:Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature[J]. Anticancer research, 2016, 36:2827-2838.
    [35] BEASLEY R, HOLLIDAY M, REDDEL H K, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma[J]. The New England journal of medicine, 2019, 380:2020-2030.
    [36] ALBERTSON T E, MURIN S, SUTTER M E, et al. The Salford Lung Study:a pioneering comparative effectiveness approach to COPD and asthma in clinical trials[J]. Pragmat Obs Res, 2017, 8:175-181.
    [37] MAGNUSSEN H, DISSE B, RODRIGUEZ-ROISIN R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD[J]. The New England journal of medicine, 2014, 371:1285-1294.
    [38] CHEN Y, WANG C, SHANG H, et al. Clinical practice guidelines in China[J]. BMJ (Clinical research ed), 2018, 360:j5158.
    [39] KEARON C, AKL E A, COMEROTA A J, et al. Antithrombotic therapy for VTE disease:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141:e419S-e496S.
    [40] KONSTANTINIDES S V, TORBICKI A, AGNELLI G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism[J]. European heart journal, 2014, 35:3033-3069, 3069a-3069k.
    [41] WANG C, ZHAI Z, YANG Y, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism:a randomized, multicenter, controlled trial[J]. Chest, 2010, 137:254-262.
    [42] FRANKLIN J M, GLYNN R J, MARTIN D, et al. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making[J]. Clinical pharmacology and therapeutics, 2019, 105:867-877.
    [43] 彭晓霞,舒啸尘,谭婧,等.基于真实世界数据评价治疗结局的观察性研究设计技术规范[J].中国循证医学杂志, 2019, 19:779-786.
    [44] CORTESE S, PANEI P, ARCIERI R, et al. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD):Data from the Italian National ADHD Registry[J]. CNS drugs, 2015, 29:865-877.
    [45] 谭婧,刘兴会,孙鑫.基于真实世界数据的疾病管理研究[J].协和医学杂志, 2019, 10:284-288.
    [46] CAMM A J, LIP G Y, DE CATERINA R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J]. European heart journal, 2012, 33:2719-2747.
    [47] ANDRADE A A, LI J, RADFORD M J, et al. Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation[J]. Journal of general internal medicine, 2015, 30:777-782.
    [48] QUANSTRUM K H, HAYWARD R A. Lessons from the mammography wars[J]. The New England journal of medicine, 2010, 363:1076-1079.
    [49] SHAUGHNESSY A F, COSGROVE L, LEXCHIN J R. The Need to Systematically Evaluate Clinical Practice Guidelines[J]. Journal of the American Board of Family Medicine:JABFM, 2016, 29:644-648.
    [50] STEELS S, VAN DER ZANDE M, VAN STAA T P. The role of real-world data in the development of treatment guidelines:a case study on guideline developers'opinions about using observational data on antibiotic prescribing in primary care[J]. BMC health services research, 2019, 19:942.
    [51] National Institue for Health and Care Excellence. NICE strategy 2021 to 2026-Dynamic, Collaborative, Excellent[EB/OL].(注明发布日期)[注明引用日期].https://www.nice.org.uk/about/who-we-are/corporate-publications/the-nice-strategy-2021-to-2026.
    [52] COLLINS R, BOWMAN L, LANDRAY M, et al. The Magic of Randomization versus the Myth of Real-World Evidence[J]. The New England journal of medicine, 2020, 382:674-678.
    [53] LEVY R I. Currently available lipid-lowering agents[J]. Hospital practice (Office ed), 1988, 23 Suppl 1:14-21.
    [54] COLLINS R, REITH C, EMBERSON J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy[J]. Lancet (London, England), 2016, 388:2532-2561.
    [55] RIMM E B, STAMPFER M J, ASCHERIO A, et al. Vitamin E consumption and the risk of coronary heart disease in men[J]. The New England journal of medicine, 1993, 328:1450-1456.
    [56] STAMPFER M J, HENNEKENS C H, MANSON J E, et al. Vitamin E consumption and the risk of coronary disease in women[J]. The New England journal of medicine, 1993, 328:1444-1449.
    [57] Heart Outcomes Prevention Evaluation Study Investigators, YUSUF S, DAGENAIS G, et al. Vitamin E supplementation and cardiovascular events in high-risk patients[J]. The New England journal of medicine, 2000, 342:154-160.
    [58] 刘晓清,孙晓川.真实世界证据[J].协和医学杂志, 2017, 8:305-310.
    [59] TUNIS S R, STRYER D B, CLANCY C M. Practical clinical trials:increasing the value of clinical research for decision making in clinical and health policy[J]. Jama, 2003, 290:1624-1632.
    [60] 谭婧,程亮亮,王雯,等.患者登记研究的策划与患者登记数据库构建:基于观察性设计的真实世界研究[J].中国循证医学杂志, 2017, 17:1365-1372.
    [61] 唐立,康德英,喻佳洁,等.实效性随机对照试验:真实世界研究的重要设计[J].中国循证医学杂志, 2017, 17:999-1004.
    [62] 孙鑫,谭婧,唐立,等.基于真实世界证据的上市后药品评价技术框架体系:思考与建议[J].中国循证医学杂志, 2018, 18:277-283.
    [63] BOOTH C M, KARIM S, MACKILLOP W J. Real-world data:towards achieving the achievable in cancer care[J]. Nat Rev Clin Oncol, 2019, 16:312-325.
    [64] 徐浩,史大卓,刘保延,等.以临床实践数据为导向构建中西医结合临床指南的设想[J].中国中西医结合杂志, 2009, 29:544-547.
    [65] 王雯,刘艳梅,谭婧,等.回顾性数据库研究的概念、策划与研究数据库构建[J].中国循证医学杂志, 2018, 18:230-237.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  89
  • HTML全文浏览量:  7
  • PDF下载量:  7
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-04-20
  • 修回日期:  2022-06-13
  • 网络出版日期:  2022-10-12

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！